Table 1 Anti-uPAR- and anti-PAI-1 immunoreactions in 60 cases of DCIS (a) and 12 cases of normal (nontumour) breast tissue (b)

From: Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue

 

Anti-uPAR IID7

Anti-uPAR HU277

Anti-uPAR 3936

Anti-PAI-1

(a) DCIS, n=60a

 Myoepithelial cells

56 (18/14/24)

41 (15/12/14)

39 (14/11/14)

34 (2/8/24)

 Tumour cells

56 (18/14/24)

50 (15/15/20)

31 (11/10/10)

56 (19/14/23)

 Macrophages

60

60

60

60

 Fibroblasts

60

60

60

60

 Endothelial cells

56 (17/16/23)

38 (14/10/14)

0

60

(b) Normal breast tissue, n=12b

 Myoepithelial cells

10

8

5

1

 Epithelial cells

10

7

4

1

 Macrophages

12

12

12

12

 Fibroblasts

12

12

12

12

 Endothelial cells

7

4

0

12

  1. uPAR=urokinase plasminogen activator receptor; PAI-1=plasminogen activator inhibitor; DCIS=ductal carcinoma in situ. For anti-uPAR immunoreaction three different antibodies were used: mAb IID7, pAb HU277 and mAb 3936.
  2. aThe VNs Classification for DCIS (n=60) was used in this study: group I (VN G1, n=20) consisted of non-high-grade DCIS without comedo-type necrosis; group II (VN G2, n=16) of non-high-grade DCIS with necrosis; and group III (VN G3, n=24) of high-grade DCIS, irrespective of comedo-type necrosis. Behind the number of positive cases the results of group I, -II and III are given within parantheses (group I/group II/group III).
  3. bImmunohistological results of 12 cases with normal (nontumour) breast tissue.
Back to article page